Last checked at 
(Sharecast News) - Biotherapeutics and reagents developer Avacta Group announced an expansion of its collaboration and license agreement with Daewoong Pharmaceutical and AffyXell Therapeutics - the joint venture established in South Korea by the two companies - to develop stem cell treatments on Wednesday.
The AIM-traded firm said the expansion would incorporate its neutralising 'Affimer' therapy for the treatment of seriously ill patients with Covid-19, and prepare for the rapid development of similar therapies for future global pandemics.
It explained that respiratory diseases such as the Covid-19 coronavirus could cause serious damage to the lungs as a result of over-activation of the patient's immune system, resulting in cytokine release syndrome that could potentially lead to multiple organ failure and death.
Stem cell therapies offered a "very promising approach" to repair the damage to lung tissues in such pulmonary diseases, by controlling the immune balance.
AffyXell Therapeutics - the cell and gene therapy joint venture between Avacta and Daewoong Pharmaceutical - is developing a novel class of mesenchymal stem cell (MSC) treatments that are engineered to also produce Affimer therapies in the patient at the site of action .
The company said the expansion of the agreement extended the scope of the partnership to include Affimer molecules that target viruses, such as coronaviruses, in order to develop therapies that repair the lung damage caused by Covid-19, while also producing neutralising Affimer molecules to prevent the progression of the disease.
AffyXell would engineer mesenchymal stem cells to express SARS-CoV-2-neutralising Affimer molecules in order to develop treatments for seriously ill Covid-19 patients, and would also prepare for the rapid development of next-generation stem cell therapies for future infectious respiratory disease outbreaks.
"AffyXell will address the need over the coming years for advanced stem cell therapies to treat lung damage caused by cytokine release syndrome suffered by Covid-19 patients and, at the same time, help prevent disease progression in these patients through the action of a neutralising Affimer therapy," said chief executive officer Dr Alastair Smith.
"More broadly, one of the key areas of unmet clinical need that AffyXell can address with its next-generation mesenchymal stem cell therapies is acute pulmonary diseases such as chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome.
"We, and our partners in South Korea, are very excited by the potential to develop life improving treatments for patients with these serious respiratory diseases as well as Covid-19."
At 1342 BST, shares in Avacta Group were down 1.43% at 147.85p.
Today 14:26
UK earnings, trading statements calendar - next 7 days
| Wednesday 24 April | |
| 1Spatial PLC | Full Year Results |
| abrdn PLC | Trading Statement |
| Ecora Resources PLC | Trading Statement |
| Fresnillo PLC | Trading Statement |
| Lloyds Banking Group PLC | Q1 Results |
| Nichols PLC | Trading Statement |
| PensionBee Group PLC | First Quarter Results |
| PZ Cussons PLC | Trading Statement |
| Quilter PLC | Q1 Results |
| Reckitt Benckiser Group PLC | Trading Statement |
| Sanderson Design Group PLC | Full Year Results |
| Serica Energy PLC | Full Year Results |
| Star Energy Group PLC | Full Year Results |
| Tortilla Mexican Grill PLC | Full Year Results |
| Tracsis PLC | Half Year Results |
| Warpaint London PLC | Full Year Results |
| Thursday 25 April | |
| Aquila European Renewables PLC | Full Year Results |
| Argo Blockchain PLC | Full Year Results |
| AstraZeneca PLC | Q1 Results |
| Barclays PLC | Q1 Results |
| Checkit PLC | Full Year Results |
| Coca-Cola Europacific Partners PLC | Trading Statement |
| Destiny Pharma PLC | Full Year Results |
| Dillistone Group PLC | Full Year Results |
| Focusrite PLC | Half Year Results |
| Gem Diamonds Ltd | Trading Statement |
| Hikma Pharmaceuticals PLC | Trading Statement |
| Hummingbird Resources PLC | Trading Statement |
| Ibstock PLC | Trading Statement |
| Inchcape PLC | Trading Statement |
| J Sainsbury PLC | Full Year Results |
| London Stock Exchange Group PLC | Q1 Results |
| Persimmon PLC | Trading Statement |
| Pinewood Technologies Group PLC | Full Year Results |
| PPHE Hotel Group Ltd | Trading Statement |
| PureTech Health PLC | Full Year Results |
| Relx PLC | Trading Statement |
| Renewi PLC | Trading Statement |
| Schroders PLC | Q1 Results |
| Skillcast Group PLC | Full Year Results |
| Travis Perkins PLC | Trading Statement |
| Trifast PLC | Trading Statement |
| Unilever PLC | Q1 Results |
| WAG Payment Solutions PLC | Trading Statement |
| Weir Group PLC | Trading Statement |
| WH Smith PLC | Half Year Results |
| WPP PLC | Trading Statement |
| Zinc Media Group PLC | Full Year Results |
| Friday 26 April | |
| Facilities by ADF PLC | Full Year Results |
| Kingspan Group PLC | Trading Statement |
| NatWest Group PLC | Q1 Results |
| Pearson PLC | Trading Statement |
| Record PLC | Trading Statement |
| Smurfit Kappa Group PLC | Trading Statement |
| Taylor Maritime Investments Ltd | Trading Statement |
| Monday 29 April | |
| Beazley PLC | Trading Statement |
| Biome Technologies PLC | Full Year Results |
| Christie Group PLC | Full Year Results |
| Gresham Technologies PLC | Full Year Results |
| Jadestone Energy PLC | Full Year Results |
| Oxford BioMedica PLC | Full Year Results |
| SpaceandPeople PLC | Full Year Results |
| Tuesday 30 April | |
| Avacta Group PLC | Full Year Results |
| Card Factory PLC | Full Year Results |
| Capital & Regional PLC | Full Year Results |
| Coca-Cola HBC AG | Trading Statement |
| Elementis PLC | Trading Statement |
| essensys PLC | Half Year Results |
| Fadel Partners Inc | Full Year Results |
| Glencore PLC | Trading Statement |
| Hargreaves Lansdown PLC | Trading Statement |
| Howden Joinery PLC | Trading Statement |
| HSBC Holdings PLC | Q1 Results |
| Kelso Group PLC | Full Year Results |
| Northcoders Group PLC | Full Year Results |
| Phoenix Spree Deutschland Ltd | Full Year Results |
| RBG Holdings PLC | Full Year Results |
| Rotork PLC | Trading Statement |
| Safestore Holdings PLC | Half Year Results |
| Shield Therapeutics PLC | Full Year Results |
| St James's Place PLC | Trading Statement |
| Whitbread PLC | Full Year Results |
| Comments and questions to newsroom@alliancenews.com | |
| A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
| Copyright 2024 Alliance News Ltd. All Rights Reserved. | |